May 16, 2017 09:35 AM EDT

OrbiMed, J&J back $24M A round for microbiome startup; Sangamo, Pfizer win FDA fast track

Shehla Shakoor

Managing Director

→ A new microbiome startup, Israel’s BiomX, has raised $24 million in a Series A — OrbiMed, Johnson & Johnson Innovation and Takeda Ventures were …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

OrbiMed, J&J back $24M A round for microbiome startup; Sangamo, Pfizer win FDA fast track

Shehla Shakoor

Managing Director

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Or­biMed, J&J back $24M A round for mi­cro­bio­me start­up; Sang­amo, Pfiz­er win FDA fast track

Shehla Shakoor

Managing Director

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

OrbiMed, J&J back $24M A round for microbiome startup; Sangamo, Pfizer win FDA fast track

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?